Rocket Pharmaceuticals Inc (RCKT)
11.79
-0.76
(-6.06%)
USD |
NASDAQ |
Jan 08, 16:00
11.69
-0.10
(-0.85%)
Pre-Market: 09:16
Rocket Pharmaceuticals SG&A Expense (Quarterly): 27.11M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Emergent BioSolutions Inc | 76.60M |
| Inogen Inc | 45.62M |
| Marinus Pharmaceuticals Inc | 12.57M |
| Spyre Therapeutics Inc | 10.65M |
| NovaBay Pharmaceuticals Inc | 2.65M |